Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at HC Wainwright

Blueprint Medicines (NASDAQ:BPMC – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday, TipRanks reports. They presently have a $100.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 101.29% from the company’s […]

Related Keywords

United States ,New Jersey ,L Becker Hewes ,Percyh Carter , ,Blueprint Medicines Corporation ,Asset Management Inc ,Securities Exchange Commission ,Jersey Common Pension Fund ,Benjaminf Edwards Company Inc ,Associates Corp ,Jefferies Financial Group ,Blueprint Medicines Company Profile Get Rating ,Citigroup ,Blueprint Medicines ,Get Rating ,Exchange Commission ,Management Inc ,Exane Derivatives ,Medicines Company Profile ,Medicines Corporation ,Nasdaq Bpmc ,Bpmc ,Medical ,Reiterated Rating ,Hc Wainwright ,